Search Results for "CT P6 Celltrion"

09:12 EST 28th January 2015 | BioPortfolio

Matching Channels


Matching News

Celltrion, Hospira to co-market biogenerics

Celltrion Inc. (biosimilars of blockbuster biologics), its Celltrion Healthcare division, and Hospira Inc. (specialty generic injectables) will collaborate on the manufacturing and supply of eight bio...

Celltrion files for Approval of Remicade Biosimilar in US

Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal anti...

Celltrion submits first biosimilar mAb application to FDA

Celltrion Inc. (KOSDAQ:068270) submitted an application to FDA for Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and

Celltrion grants Remsima marketing rights to Mundipharma

Celltrion Inc. (KOSDAQ:068270) subsidiary Celltrion Healthcare Hungary Kft granted Mundipharma International Ltd. (Cambridge, U.K.) exclusive distribution rights to market Remsima infliximab in the U....

Celltrion seeks FDA approval of biosimilar version of Remicade

Celltrion has filed an application with the FDA for approval to market Remsima, its biosimilar version of Johnson & Johnson a -More- 

Celltrion files for US FDA approval of Remsima®

Remsima® is expected to be the first biosimilar monoclonal antibody to be filed through United States of America Food and Drug Administration’s biosimilar regulatory approval pathway, the Biologics...

Celltrion files for US FDA approval of Remsima biosimilar

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US Food and Drug Administration approval for Remsima, its biosimilar infliximab, the active ingredien...

Celltrion, Mundipharma deal

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement